Compare Gilead Sciences, Inc. (GILD) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Otis Worldwide Corp — how do they compare? Gilead Sciences, Inc. trades at $132.92 (market cap $163.51B), while Otis Worldwide Corp trades at $74.08 (market cap $27.70B). The key difference: Gilead Sciences, Inc. is far larger — about 5.9× Otis Worldwide Corp's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | OTIS | |
|---|---|---|
Market Cap | $163.51B | $27.70B |
Sector | Health | Industrials |
52-Week High | $155.80 | $101.07 |
52-Week Low | $108.22 | $69.34 |
Enterprise Value | $178.05B | $35.09B |
Dividend Yield | 2.49% | 2.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Otis Worldwide (OTIS) trades at $72.56, down 1.17% on the day, with technical indicators showing a bearish bias. The company reported mixed recent earnings, beating in Q3 2025 but missing in Q4 2025 and Q1 2026. Revenue growth remains steady, with 2025 revenue of $14.43B and a net income margin of 10.11%. Recent corporate news includes a 5% dividend increase to $0.44 per share and new modernization solution launches in EMEA and Brazil.
The outlook presents a dichotomy: a compelling valuation disconnect versus near-term operational headwinds. The stock trades at a significant discount to the $91.00 analyst consensus target, offering potential upside. However, risks include recent earnings misses, a challenging debt-to-asset ratio of 75.54% (2025), and margin pressure from tariffs and investments, as noted in Q1 2026 results (Zacks, April 22, 2026).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
